| Top Medical Center Lp | |
|
456 N New Ballas Rd Ste 101 Creve Coeur MO 63141-6850 | |
| (314) 384-3600 | |
| Not Available |
| Full Name | Top Medical Center Lp |
|---|---|
| Speciality | Family Medicine |
| Location | 456 N New Ballas Rd Ste 101, Creve Coeur, Missouri |
| Authorized Official Name and Position | Chandrachur Banerjee (AUTHORIZED OFFICIAL) |
| Authorized Official Contact | 3143843600 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Top Medical Center Lp 456 N New Ballas Rd Ste 101 Creve Coeur MO 63141-6850 Ph: (314) 384-3600 | Top Medical Center Lp 456 N New Ballas Rd Ste 101 Creve Coeur MO 63141-6850 Ph: (314) 384-3600 |
| NPI Number | 1215504394 |
|---|---|
| Provider Enumeration Date | 06/08/2021 |
| Last Update Date | 02/16/2022 |
| Medicare PECOS PAC ID | 7012312606 |
|---|---|
| Medicare Enrollment ID | O20210819001947 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215504394 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Manish Suthar |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1326123100 PECOS PAC ID: 7911085857 Enrollment ID: I20100514000166 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Provider Name | Edwin D Dunteman |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1427030956 PECOS PAC ID: 6507931540 Enrollment ID: I20100709000479 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Provider Name | Lindsay Jones |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275169567 PECOS PAC ID: 5496185704 Enrollment ID: I20200428000493 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Provider Name | Courtney Elizabeth Lemmon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942829676 PECOS PAC ID: 2961812722 Enrollment ID: I20201105001642 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Provider Name | Jeffrey Wilcox |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164791703 PECOS PAC ID: 1052717105 Enrollment ID: I20210915001007 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Provider Name | Bankole Bidemi Aluko |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851983910 PECOS PAC ID: 8224435474 Enrollment ID: I20210930001878 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Provider Name | Kathleen Delain Decker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780168823 PECOS PAC ID: 9931507175 Enrollment ID: I20211001001982 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
| Provider Name | Faye Monahan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053074997 PECOS PAC ID: 4183013162 Enrollment ID: I20211112000655 |
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
News Archive
A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
› Verified 1 days ago
Mid-town Medical Practice, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 9 Sackston Woods Ln, Creve Coeur, MO 63141 Phone: 314-651-6132 | |
Renewed Health 180 Lp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 456 N New Ballas Rd Ste 101a, Creve Coeur, MO 63141 Phone: 314-866-9940 | |
4ever-young Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 11716 Studt Ave, Creve Coeur, MO 63141 Phone: 314-330-8117 | |
Allies 4 Health Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 522 N New Ballas Rd Ste 245, Creve Coeur, MO 63141 Phone: 314-472-8333 | |
Midwest Consulting And Ime Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 763 S New Ballas Rd, Suite 230, Creve Coeur, MO 63141 Phone: 314-681-2800 Fax: 314-432-5088 | |
Missouri Pain Specialists, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 12607 Olive Blvd, Creve Coeur, MO 63141 Phone: 314-327-8070 Fax: 314-228-1891 |